多西环素-莫西沙星与多西环素-2.5g阿奇霉素耐药指导治疗生殖支原体感染的疗效与耐受性
该研究纳入2017—2018年墨尔本性健康中心383例生殖支原体感染患者,采用耐药指导策略:敏感者用多西环素后2.5g阿奇霉素,耐药者用多西环素后莫西沙星。微生物治愈率分别为95.4%和92.0%,新发大环内酯耐药4.6%,支持现行指南方案。
要点
- 多西环素-阿奇霉素治愈率95.4%,多西环素-莫西沙星92.0%
- 新发大环内酯耐药率4.6%
- 耐药指导策略支持莫西沙星及2.5g阿奇霉素方案
核心结论
- 耐药指导治疗下多西环素-2.5g阿奇霉素与多西环素-莫西沙星均获高治愈率,支持现行指南方案。
研究设计与样本
- 2017—2018年墨尔本性健康中心性传播感染综合征患者,多西环素7天后按耐药结果分组治疗,治愈检测于用药后14—28天。
- 共纳入383例:81例女性、106例异性恋男性、196例男男性行为者。
主要发现
- 多西环素-阿奇霉素微生物治愈率95.4%(95%CI 89.7—98.0)。
- 多西环素-莫西沙星微生物治愈率92.0%(95%CI 88.1—94.6)。
- 新发大环内酯耐药检出率4.6%。
- 合并既往RGT研究(n=186)后阿奇霉素方案合并治愈率95.7%(95%CI 91.6—97.8)。
- 大环内酯耐药病例中ParC突变占22%。
关键数值与推荐
- 大环内酯敏感者:阿奇霉素1g后500mg每日1次共3天(总2.5g)。
- 大环内酯耐药者:莫西沙星400mg每日1次共7天。
- 所有患者先予多西环素7天。
- 治愈检测推荐于抗菌药物后14—28天。
临床怎么用
- 对生殖支原体感染可先予多西环素7天,再依据大环内酯耐药检测选择阿奇霉素2.5g或莫西沙星7天方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Macrolide resistance in Mycoplasma genitalium (MG) exceeds 50% in many regions, and quinolone resistance is increasing. We recently reported that resistance-guided therapy (RGT) using doxycycline followed by sitafloxacin or 2.5 g azithromycin cured 92% and 95% of macrolide-resistant and macrolide-susceptible infections, respectively. We present data on RGT using doxycycline-moxifloxacin, the regimen recommended in international guidelines, and extend data on the efficacy of doxycycline-2.5 g azithromycin and de novo macrolide resistance. METHODS: Patients attending Melbourne Sexual Health Centre between 2017 and 2018 with sexually transmitted infection syndromes were treated with doxycycline for 7 days and recalled if MG-positive. Macrolide-susceptible cases received 2.5 g azithromycin (1 g, then 500 mg daily for 3 days), and resistant cases moxifloxacin (400 mg daily, 7 days). Test of cure was recommended 14-28 days post-antimicrobials. RESULTS: There were 383 patients (81 females/106 heterosexual males/196 men who have sex with men) included. Microbial cure following doxycycline-azithromycin was 95.4% (95% confidence interval [CI], 89.7-98.0) and doxycycline-moxifloxacin was 92.0% (95% CI, 88.1-94.6). De novo macrolide resistance was detected in 4.6% of cases. Combining doxycycline-azithromycin data with our prior RGT study (n = 186) yielded a pooled cure of 95.7% (95% CI, 91.6-97.8). ParC mutations were present in 22% of macrolide-resistant cases. CONCLUSIONS: These findings support the inclusion of moxifloxacin in resistance-guided strategies and extend the evidence for 2.5 g azithromycin and presumptive use of doxycycline. These data provide an evidence base for current UK, Australian, and European guidelines for the treatment of MG.
引用
- Durukan D, Read TRH, Murray G, et al. Resistance-Guided Antimicrobial Therapy Using Doxycycline-Moxifloxacin and Doxycycline-2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability. Clin Infect Dis. 2020. PMID: 31629365. doi:10.1093/cid/ciz1031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。